Efficacy of treating acute cerebral infarction by Batroxobin combined with Aspirin

Objective To investigate the effect and safety of Batroxobin (DF-521) combined with Aspirin (ASA) in the treatment of acute cerebral infarction. Methods 102 patients with acute cerebral infarction were enrolled in the study and all the patients were divided into three groups: ASA group (n=23), Batroxobin group (n=35) and ASA combined with Batroxobin group (n=44). Platelet count, blood viscosity, platelet aggregation test (PAgT), fibrinogen, coagulation studies (PT, APTT, INR), TXB2, imaging, National Institutes of Health Stroke Scale (NIHSS) and Modified Barthel Index (MBI) were measured or assessed before and after treatment, respectively. Hemorrhage rate (including brain and other organs) as one of complication was also investigated.Results After treatments, ASA combined with Batroxobin group showed the strongest inhibition of platelet aggregation among the three groups (all P0.05). TXB2 level in ASA group and ASA combined with Batroxobin group was significantly lower than in Batroxobin group (all P0.05). Plasma fibrinogen levers and high sheer rate decreased significantly in Batroxobin group and ASA combined with Batroxobin group compared with ASA group ( P0.05, P0.01). Functional recovery in ASA combined with Batroxobin group (70.45%) was superior to ASA group (17.39%) and Batroxobin group (45.71%). There was no significant difference in systemic hemorrhage among the three groups ( P0.05). A follow up of 3 months showed that the scores of NIHSS and MBI in ASA combined with Batroxobin group were better than those in the other two groups (all P0.001).Conclusion ASA combined with Batroxobin shows better clinic effect and no more hemorrhagic risk than ASA or Batroxobin in the therapy of acute cerebral infarction.